Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLDNASDAQ:GERNNASDAQ:IMGNNASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$5.71+1.2%$6.37$5.59▼$12.65$1.74B0.543.09 million shs5.71 million shsGERNGeron$1.42-6.0%$1.41$1.17▼$5.06$961.75M0.6911.19 million shs8.83 million shsIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsIRWDIronwood Pharmaceuticals$0.67-4.0%$0.71$0.53▼$7.11$113.53M0.242.56 million shs1.37 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics0.00%-6.47%-9.32%-35.10%-44.10%GERNGeron0.00%0.00%+4.14%-13.71%-67.53%IMGNImmunoGen0.00%0.00%0.00%0.00%0.00%IRWDIronwood Pharmaceuticals0.00%+13.16%+23.89%-52.91%-88.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFOLDAmicus Therapeutics3.9893 of 5 stars3.42.00.04.31.80.01.9GERNGeron3.1894 of 5 stars3.42.00.01.31.41.70.6IMGNImmunoGenN/AN/AN/AN/AN/AN/AN/AN/AIRWDIronwood Pharmaceuticals4.3621 of 5 stars4.13.00.03.41.10.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.70Moderate Buy$16.22184.10% UpsideGERNGeron 2.78Moderate Buy$5.06256.51% UpsideIMGNImmunoGen 0.00N/AN/AN/AIRWDIronwood Pharmaceuticals 2.13Hold$4.78610.33% UpsideCurrent Analyst Ratings BreakdownLatest IMGN, FOLD, IRWD, and GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.505/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.004/16/2025IRWDIronwood PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025IRWDIronwood PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.004/15/2025IRWDIronwood PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $0.704/14/2025IRWDIronwood PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.004/14/2025IRWDIronwood PharmaceuticalsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$528.29M3.33N/AN/A$0.65 per share8.78GERNGeron$76.99M11.75N/AN/A$0.46 per share3.09IMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99IRWDIronwood Pharmaceuticals$351.41M0.31$0.05 per share14.19($1.88) per share-0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$56.11M-$0.09N/A13.28N/A-5.41%4.67%1.05%8/14/2025 (Estimated)GERNGeron-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)IMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AIRWDIronwood Pharmaceuticals$880K-$0.20N/A2.69N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)Latest IMGN, FOLD, IRWD, and GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AIMGNImmunoGenN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics2.023.342.47GERNGeron0.447.876.97IMGNImmunoGen0.135.705.65IRWDIronwood PharmaceuticalsN/A3.343.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AGERNGeron73.71%IMGNImmunoGen90.50%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%GERNGeron7.42%IMGNImmunoGen5.07%IRWDIronwood Pharmaceuticals12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableGERNGeron70636.92 million589.66 millionOptionableIMGNImmunoGen277266.26 million252.76 millionOptionableIRWDIronwood Pharmaceuticals220161.82 million141.27 millionOptionableIMGN, FOLD, IRWD, and GERN HeadlinesRecent News About These CompaniesWhy Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?June 6, 2025 | zacks.com426,138 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by Universal Beteiligungs und Servicegesellschaft mbHJune 3, 2025 | marketbeat.comZacks Research Issues Pessimistic Estimate for IRWD EarningsJune 2, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Hold" by BrokeragesJune 1, 2025 | marketbeat.comZacks Research Issues Optimistic Outlook for IRWD EarningsMay 31, 2025 | marketbeat.comMan Group plc Has $1.57 Million Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)May 26, 2025 | marketbeat.comWhy Ironwood Pharmaceuticals, Inc.’s (IRWD) Stock Is Down 5.28%May 15, 2025 | aaii.comWhy Ironwood Pharmaceuticals, Inc.’s (IRWD) Stock Is Up 5.49%May 10, 2025 | aaii.comPacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc.May 8, 2025 | gurufocus.comPacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc.May 8, 2025 | gurufocus.comIRWD Stock Down 15% as Q1 Earnings & Revenues Miss EstimatesMay 8, 2025 | zacks.comIronwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2025 | zacks.comIronwood Pharmaceuticals Reports First Quarter 2025 ResultsMay 7, 2025 | businesswire.comAnalysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out forMay 1, 2025 | zacks.comIronwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comIronwood Raises 2025 Adj. EBITDA OutlookApril 26, 2025 | nasdaq.comIronwood backs FY25 revenue view $260M-$290M, consensus $287.07MApril 26, 2025 | markets.businessinsider.comIronwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025April 25, 2025 | gurufocus.comIronwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares riseApril 25, 2025 | msn.comIronwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock NewsApril 25, 2025 | gurufocus.comIronwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA GuidanceApril 25, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMGN, FOLD, IRWD, and GERN Company DescriptionsAmicus Therapeutics NASDAQ:FOLD$5.71 +0.07 (+1.24%) Closing price 04:00 PM EasternExtended Trading$5.81 +0.10 (+1.73%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Geron NASDAQ:GERN$1.42 -0.09 (-5.96%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.06%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.ImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Ironwood Pharmaceuticals NASDAQ:IRWD$0.67 -0.03 (-4.02%) Closing price 04:00 PM EasternExtended Trading$0.71 +0.04 (+6.03%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
